
Bristol-Myers Squibb Company
BMYHealthcare|Drug Manufacturers - General|US
$62.14
-0.99 (-1.57%)
DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16
Clinical Trials (104)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07681076 Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers | Healthy Volunteers | P4 | Recruiting | 180 | RCT, Open-label | KarXT, Trimethobenzamide, Ondansetron, Meclizine |
| NCT06126224 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | Psychosis Associated With Alzheimer's Disease | P3 | Recruiting | 500 | RCT, Double-blind | KarXT, Placebo |
| NCT05511363 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Psychosis Associated With Alzheimer's Disease | P3 | Recruiting | 410 | RCT, Double-blind | KarXT, Placebo |
| NCT07424404 A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents | Schizophrenia, Autism-Related Irritability | P3 | Recruiting | 400 | Open-label | KarXT, KarX-EC |
| NCT05980949 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Psychosis Associated With Alzheimer's Disease | P3 | Recruiting | 1,000 | Open-label | KarXT |
| NCT06585787 A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Alzheimer Disease | P3 | Recruiting | 406 | RCT, Double-blind | KarXT, Placebo |
| NCT07686263 Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia | Schizophrenia | P3 | Recruiting | 472 | RCT, Double-blind | Xanomeline/Trospium Chloride, Placebo |
| NCT06615479 A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Relapsed or Refractory Multiple Myeloma (RRMM) | P3 | Recruiting | 440 | RCT, Open-label | BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib |
| NCT05702034 A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE | Ischemic Stroke; Ischemic Attack, Transient | P3 | Active | 12,523 | RCT, Double-blind | Milvexian, Placebo |
| NCT07015242 A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Lymphoma | P2 | Recruiting | 65 | Open-label | Rituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel, Fludarabine, Cyclophosphamide, Calcium folinate |
| NCT06297226 Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P2 | Recruiting | 230 | Open-label | Arlocabtagene Autoleucel |
| NCT03527108 Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | Non Small Cell Lung Cancer | P2 | Active | 36 | Open-label | Nivolumab, Ramucirumab |
| NCT02693535 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Lymphoma, Non-Hodgkin, Multiple Myeloma | P2 | Recruiting | 4,200 | Open-label | Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD) |
| NCT02925234 The Drug Rediscovery Protocol (DRUP Trial) | Cancer, Tumors | P2 | Recruiting | 1,550 | Open-label | Panitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib |
| NCT07015983 A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | Lupus Erythematosus, Systemic, Lupus Nephritis | P2 | Active | 89 | Open-label | CC-97540, Fludarabine, Cyclophosphamide |
| NCT06121843 A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Recruiting | 187 | Open-label | BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone |
| NCT07204418 A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants | Healthy Volunteers | P1 | Recruiting | 56 | Open-label | Xanomeline/ Trospium Chloride |
| NCT02498912 Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors | Solid Tumors | P1 | Active | 18 | Open-label | Cyclophosphamide, Fludarabine |
| NCT07115745 A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases | Refractory Autoimmune Diseases | P1 | Recruiting | 125 | Open-label | Fludarabine, Cyclophosphamide, Tocilizumab |
| NCT06153251 A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma | P1 | Recruiting | 187 | Open-label | BMS-986453, Fludarabine, Cyclophosphamide |
| NCT06220201 A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | Multiple Sclerosis, Myasthenia Gravis | P1 | Active | 120 | Open-label | CC-97540, Fludarabine, Cyclophosphamide |
| NCT03085173 A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Chronic Lymphocytic Leukemia (CLL), Relapsed | P1 | Active | 39 | Open-label | EGFRt/19-28z/4-1BBL CAR T cells |
| NCT05869955 A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy | P1 | Active | 270 | Open-label | CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab |
| NCT06788652 A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | Mantle Cell Lymphoma (MCL) | Recruiting | 300 | — | Lisocabtagene maraleucel | |
| NCT06788639 A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Recruiting | 300 | — | Lisocabtagene maraleucel | |
| NCT06794268 A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting | Follicular Lymphoma | Recruiting | 300 | — | Lisocabtagene maraleucel | |
| NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People. | HIV Infections, Hepatitis B | Recruiting | 24,258 | — | — | |
| NCT00505245 New Assessment System in Measuring Symptom Distress in Cancer Patients | Caregiver, Health Care Provider | Recruiting | 6,500 | — | — | |
| NCT05918666 National Register of Actionable Mutations | Solid Tumours in Advanced Stages | Active | 2,098 | — | — | |
| NCT01848028 PsoBest - The German Psoriasis Registry | Psoriasis, Psoriatic-arthritis | Recruiting | 3,500 | — | — | |
| NCT02622581 Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients | Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic | Recruiting | 14,500 | — | — | |
| NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients | Rheumatoid Arthritis, Psoriatic Arthritis | P4 | Completed | 841 | RCT, Open-label | Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab |
| NCT00977938 The Dual Antiplatelet Therapy Study (DAPT Study) | Coronary Artery Disease | P4 | Completed | 25,682 | RCT, Double-blind | Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin |
| NCT00169819 EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study | Coronary Artery Disease, Ischemia | P4 | Completed | 1,000 | RCT, Open-label | Abciximab |
| NCT01524705 FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) | Type 2 Diabetes | P4 | Completed | 102 | RCT, Double-blind | Insulin Glargine, Metformin, Prandial insulin, Exenatide |
| NCT01106534 XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort | Chronic Total Occlusion of Coronary Artery, Vascular Disease | P4 | Completed | 870 | RCT, Double-blind | placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin |
| NCT07257120 KarXT Concentrations in the Breast Milk and Plasma of Lactating Females | Healthy Volunteers | P4 | Completed | 10 | Open-label | Xanomeline/trospium chloride |
| NCT00816959 Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma | Hodgkin's Lymphoma | P3 | Unknown | 1,200 | RCT, Open-label | R-mabHDI and ABVD, ABVD |
| NCT04820309 An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) | Schizophrenia | P3 | Completed | 566 | Open-label | Xanomeline and Trospium Chloride Capsules |
| NCT07335562 A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis | Systemic Sclerosis | P3 | Not Yet Recruiting | 92 | RCT, Open-label | BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib |
| NCT04738123 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3) | Schizophrenia, Schizophrenia; Psychosis | P3 | Completed | 256 | RCT, Double-blind | Xanomeline and Trospium Chloride Capsules, Placebo |
| NCT05919823 A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia | Schizophrenia | P3 | Completed | 202 | RCT, Double-blind | Xanomeline and Trospium Chloride Capsules, Placebo |
| NCT05643170 An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia | Schizophrenia | P3 | Terminated | 4 | Open-label | Xanomeline and Trospium Chloride Capsules |
| NCT00077233 FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum | Colorectal Cancer | P3 | Terminated | 238 | RCT, Open-label | cetuximab, 5-FU, irinotecan, leucovorin, oxaliplatin |
| NCT06205290 A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | Leukemia, Lymphocytic, Chronic, B-Cell | P3 | Withdrawn | — | RCT, Open-label | Liso-cel, Idelalisib, Rituximab, Bendamustine, Fludarabine, Cyclophosphamide |
| NCT00063141 Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer | Colorectal Cancer | P3 | Completed | 1,302 | RCT, Open-label | cetuximab, Irinotecan, Irinotecan |
| NCT04659174 An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) | Schizophrenia | P3 | Completed | 152 | Open-label | Xanomeline and Trospium Chloride Capsules |
| NCT05145413 A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | Schizophrenia | P3 | Completed | 396 | RCT, Double-blind | Xanomeline and Trospium Chloride Capsules, Placebo |
| NCT05304767 An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | Schizophrenia | P3 | Completed | 290 | Open-label | Xanomeline and Trospium Chloride Capsules |
| NCT04518410 ACTIV-2: A Study for Outpatients With COVID-19 | Coronavirus, Covid19 | P2P3 | Completed | 4,044 | RCT, Double-blind | bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg |
| NCT06572449 Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia | Schizophrenia | P3 | Completed | 173 | Open-label | KarXT |
| NCT00061815 Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer | Colorectal Cancer | P3 | Completed | 102 | RCT, Open-label | cetuximab, oxaliplatin, leucovorin, 5-fluorouracil, 5-fluorouracil, cetuximab |
| NCT06313996 A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | Relapsed or Refractory Follicular Lymphoma | P3 | Withdrawn | — | RCT, Single-blind | Cyclophosphamide, Doxorubicin, Vincristine, Rituximab, Prednisone, Bendamustine, Lenalidomide, Fludarabine, Liso-cel |
| NCT04659161 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) | Schizophrenia, Schizophrenia; Psychosis | P3 | Completed | 252 | RCT, Double-blind | Xanomeline and Trospium Chloride Capsules, Placebo |
| NCT00063388 Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer | Non-Small-Cell Lung Cancer | P2 | Completed | 66 | Open-label | Cetuximab |
| NCT00527111 Pre-op Rectal ChemoRad +/- Cetuximab | Rectal Cancer | P2 | Completed | 139 | RCT, Open-label | Cetuximab, 5-fluorouracil |
| NCT03370276 Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx | P1P2 | Completed | 95 | Open-label | Nivolumab, Cetuximab |
| NCT00797472 Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | Hodgkin's Disease | P2 | Unknown | 120 | RCT, Open-label | R-mabHD, ABVD |
| NCT00448097 Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy | Prostatic Neoplasms | P2 | Terminated | 7 | RCT, Open-label | cetuximab, docetaxel |
| NCT00216203 Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P1P2 | Completed | 36 | Open-label | Pemetrexed, Cetuximab |
| NCT00645593 Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer | Bladder Cancer | P2 | Completed | 89 | RCT, Open-label | Gemcitabine,, Cisplatin, Cetuximab |
| NCT00444678 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | Colorectal Cancer, Neoplasm Metastasis | P2 | Completed | 36 | Open-label | Cetuximab, Oxaliplatin, Capecitabine |
| NCT00193310 Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer | Lung Cancer | P2 | Completed | 250 | RCT, Open-label | Paclitaxel, Carboplatin |
| NCT04151563 A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Carcinoma, Non-small Cell Lung Cancer | P1P2 | Withdrawn | — | RCT, Open-label | nivolumab, ipilimumab, cabozantinib, docetaxel, ramucirumab, lucitanib |
| NCT00725400 Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma | Colorectal Carcinoma | P2 | Withdrawn | 450 | RCT, Open-label | — |
| NCT00857246 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer | Gastric Cancer, Stomach Cancer | P2 | Completed | 30 | Open-label | Cetuximab, Irinotecan, Cisplatin, 5-FU |
| NCT00097227 Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | P2 | Completed | 165 | RCT, Open-label | Cetuximab, Carboplatin, Paclitaxel |
| NCT00128856 Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | Breast Cancer | P2 | Completed | 46 | Open-label | Gemcitabine, Adriamycine, Paclitaxel |
| NCT00055419 A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer | Colorectal Neoplasms | P2 | Completed | 744 | Open-label | Cetuximab |
| NCT03502746 Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | Mesothelioma, Malignant | P2 | Terminated | 34 | Open-label | Nivolumab, Ramucirumab |
| NCT03697252 A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia | Schizophrenia | P2 | Completed | 182 | RCT, Double-blind | Xanomeline and Trospium Chloride Capsules, Placebo Capsules |
| NCT07603557 Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) | Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia | P2 | Not Yet Recruiting | 52 | Open-label | BMS-986353, Fludarabine Phosphate, Cyclophosphamide |
| NCT00148109 Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas | Sarcoma | P2 | Completed | 36 | Open-label | Cetuximab, Cetuximab |
| NCT00082212 A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | Ovarian Cancer | P2 | Terminated | 25 | Open-label | Cetuximab |
| NCT00063401 Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Ovarian Cancer, Peritoneal Neoplasms | P2 | Completed | 39 | Open-label | Cetuximab:, Paclitaxel, Carboplatin |
| NCT00117962 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer | Lung Cancer | P2 | Completed | 109 | RCT, Open-label | cetuximab, carboplatin, pemetrexed disodium |
| NCT00292955 Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma | Cancer of the Cervix | P2 | Unknown | 30 | Open-label | Cetuximab |
| NCT00083720 Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy | Colorectal Neoplasms, Metastases | P2 | Completed | 87 | Open-label | cetuximab |
| NCT00562419 CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme | P2 | Unknown | 72 | RCT, Open-label | CT-322, irinotecan hydrochloride |
| NCT00097214 Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | P2 | Completed | 57 | Open-label | Carboplatin, Cetuximab |
| NCT00580073 Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum | Rectal Cancer | P2 | Terminated | 6 | Open-label | FOLFOX4, Cetuximab |
| NCT02423343 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | Solid Tumor, Non-Small Cell Lung Cancer Recurrent | P1P2 | Completed | 41 | Open-label | Galunisertib, Nivolumab |
| NCT05706753 A Study of Milvexian in Healthy Adult Females | Healthy Female | P1 | Completed | 20 | Open-label | Milvexian, Midazolam, Ethinylestradiol, Drospirenone |
| NCT05375084 SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | Non Small Cell Lung Cancer, Solid Tumor | P1 | Terminated | 21 | Open-label | BBP-398 with nivolumab |
| NCT03338972 Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma | Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | P1 | Completed | 28 | Open-label | Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143, Cyclophosphamide, Fludarabine |
| NCT03502577 BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma | Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | P1 | Terminated | 19 | Open-label | BCMA-specific CAR-expressing T Lymphocytes, Cyclophosphamide, Fludarabine, Gamma-Secretase Inhibitor LY3039478 |
| NCT02831231 Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium | Schizophrenia | P1 | Completed | 70 | RCT, Double-blind | xanomeline tartrate, Trospium chloride |
| NCT06729970 A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants | Healthy Volunteers | P1 | Completed | 133 | Open-label | Xanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine |
| NCT06605950 A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 78 | RCT, Double-blind | KarXT, KarX-EC, Placebo, Omeprazole |
| NCT02706405 JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma | P1 | Terminated | 30 | Open-label | Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab, Fludarabine |
| NCT00374179 CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma | Cancer | P1 | Completed | 40 | Open-label | CT-322 |
| NCT00768911 CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme | Glioblastoma Multiforme | P1 | Unknown | 30 | Open-label | CT-322, Temozolomide |
| NCT07118215 A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin | Healthy Volunteers | P1 | Completed | 62 | Open-label | KarXT, Midazolam, Fexofenadine, Digoxin |
| NCT03070327 BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma | Multiple Myeloma | P1 | Completed | 20 | Open-label | EGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide. |
| NCT07848295 A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) | Clear Cell Renal Cell Carcinoma (ccRCC) | P1 | Not Yet Recruiting | 112 | Open-label | BMS-986527, Nivolumab, Cabozantinib |
| NCT00291707 Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer | Head and Neck Cancer | P1 | Completed | 40 | Open-label | Cetuximab, Pemetrexed |
| NCT03103971 huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | P1 | Terminated | 55 | Open-label | Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Cyclophosphamide, Fludarabine |
| NCT00211263 Bipolar Disorder Research Study for Ages 12 and Older | Bipolar Disorder | N/A | Completed | 750 | RCT, Open-label | mood stabilizer |
| NCT01565863 Progressive Goal Attainment Program for Veterans | Mental Disorders, Worries; Pain or Disability | N/A | Completed | 199 | RCT, Open-label | — |
| NCT01281228 The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes | Diabetes Mellitus, Diabetes Mellitus, Type 2 | N/A | Completed | 48 | RCT, Single-blind | exenatide, exenatide + exendin (9-39), placebo |
| NCT00149591 The Viability-Guided Angioplasty After Acute Myocardial Infarction-Trial (The VIAMI-Trial) | Myocardial Infarction, Coronary Artery Disease | N/A | Unknown | 300 | RCT, Open-label | — |
| NCT05826756 Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting | Lung Cancer Patients, Caregivers | Unknown | 1,300 | — | — | |
| NCT02075697 Spanish Registry of Systemic Treatments in Psoriasis | Psoriasis | Unknown | 3,500 | — | — | |
| NCT04734769 Embryos With Preimplantation Genetic Testing for Aneuploidies (PGT-A) Inconclusive Result: Clinical Implications | Embryo Disorder | Unknown | 600 | — | — |